Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
64 participants
OBSERVATIONAL
2023-09-25
2024-09-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Renal Cell Arrest and Damage Biomarkers in Progression and Outcome of Septic AKI
NCT06064487
Predictive Value of Doppler RSI for Prediction of AKI in Septic Patients in ICU
NCT04426032
Is There Any Prognostic Value of Serum Uromodulin in Sepsis Induced AKI.
NCT07295392
Renal Arterial Resistive Index Versus Novel Biomarkers for Early Prediction of Sepsis Associated-acute Kidney Injury
NCT03799159
Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
NCT04986137
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Blood samples will be collected within 24 hours of AKI diagnosis for analysis of Blood Urea Nitrogen (BUN) and serum Albumin levels.
Blood Urea Nitrogen to serum Albumin ratio (B/A) will be calculated by dividing the BUN of a patient by their serum Albumin levels.
Laboratory parameters also will include pH, lactate (Lac), base excess (BE), hemoglobin (Hb), platelet (PLT) count, white blood cell (WBC) count, bilirubin, hematocrit (HCT), creatinine (Cr), serum sodium (Na), serum potassium (K), serum calcium (Ca), serum magnesium (Mg), triglyceride (TG), aspartate aminotransferase (ALT), alanine aminotransferase (AST), prothrombin time (PT), and activated partial thromboplastin time (APTT) values.
Follow-up will be conducted for all enrolled patients for 30 days from admission to record mortality and the cause of death.
Study population will be divided into survival and non-survival groups based on their 30-day survival status
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Fulfilled the diagnostic criteria of Sepsis 3.0 (defined as a suspected or confirmed infection with a sequential organ failure assessment (SOFA) score of 2 or higher)
3. Developed AKI during hospitalization according to Kidney Disease: Improving Global Outcomes (KDIGO) guideline
Exclusion Criteria
2. AKI occurred before current hospital admission.
3. AKI is supposed to be secondary to causes other than sepsis.
4. Receiving renal replacement therapy at the time of admission.
5. Diagnosis with chronic kidney disease.
6. Diagnosis with liver failure.
7. Pregnant or lactating.
8. There was insufficient data for analysis.
9. Patients who had received Human serum Albumin infusion 3 days before ICU admission.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University
Cairo, Abbassia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BAR in septic AKI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.